Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

GSK Gives Update on Plans to Share Detailed Clinical Trial Data

Published: Wednesday, May 08, 2013
Last Updated: Wednesday, May 08, 2013
Bookmark and Share
New online system will enable researchers to request access to patient level data from GSK clinical trials to help further scientific understanding and improve patient care.

GlaxoSmithKline (GSK) announced progress on its commitment to share more detailed data from its clinical trials. A new online system available on ( will enable researchers to request access to anonymised patient level data that sit behind the results of clinical trials. It is hoped that sharing these data with researchers will help to further scientific research, increase understanding of new and current medicines and ultimately improve patient care.

Consistent with expectations of good scientific practice, researchers can request access by providing   a scientific protocol with a commitment to publish their findings. External independent experts appointed by GSK to advise on the development of the system will be the initial review panel, responsible for assessing research proposals made through the system.

Access to the data from GSK’s studies will be provided on a password protected website to help protect research participants’ privacy and ensure the data are used for the approved scientific purpose.

This initiative is a step towards the ultimate aim of the clinical research community developing a broader system where researchers are able to access data from clinical trials conducted by multiple organisations. This system would be run by an independent third party who would be responsible for appointing and overseeing a review panel to assess research proposals. GSK is already in discussions with interested parties to encourage the development of such a system.

Patrick Vallance, GSK’s President of Pharmaceuticals R&D, said: “When people volunteer for clinical trials they expect that the results will be used to help others. We are absolutely committed to sharing data so that researchers can examine the details more closely, do their own analyses and learn more about medicines and how they can best be used. Consistent with good scientific practice, researchers will be required to submit a research plan and to commit to transparency in the publication of their work.

“We are the first organisation to develop a system for sharing detailed clinical data in this way. Now we want to see this initiative transition to a broader independent model that brings together data from multiple organisations. We are keen for this to progress and hope such a system can be put in place by a third party in the public or charitable sector as soon as possible.”

Studies will be listed on GSK’s system once a medicine has been approved by regulators or terminated from development and the study has been accepted for publication. Studies that do not progress to publication will also be included.  The system already includes global studies conducted since 2007. Over the next two years global studies going back to the formation of GSK in December 2000 will be added. In addition, all studies (including local studies) starting in or after 2013 will be included.

GSK has taken a number of steps over the years to share more information from clinical trials that evaluate its medicines:

•    The company registers and posts summary information about each clinical trial it begins.
•    Results of all clinical trials – whether positive or negative – are made available on a website accessible to all. Today this website includes almost 5,000 clinical trial result summaries and receives an average of almost 11,000 visitors each month.
•    The company has also committed to seek publication of the results of all of its clinical trials that evaluate its medicines in peer-reviewed scientific journals.
•    Most recently, in February 2013, GSK signed up to the AllTrials campaign for clinical data transparency and committed to make its clinical study reports (CSRs) publicly available through its clinical trials register after approval, termination and publication. CSRs are formal study reports that provide more details on the design, methods and results of clinical trials and form the basis of submissions to regulatory agencies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Receives Positive CHMP Opinion in Europe for Asthma Therapeutic
GlaxoSmithKline has announced that the CHMP of the EMA has issued a positive opinion recommending marketing authorisation for mepolizumab, which will be commercialised under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Monday, September 28, 2015
GSK, Francis Crick Institute Collaborate
This partnership sets out to explore new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.
Monday, July 20, 2015
GSK’s 2015 Discovery Fast Track Challenge
Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US.
Wednesday, March 25, 2015
GSK to Invest £200 Million in UK Manufacturing
The series of investments will support the delivery of the company’s pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.
Thursday, December 12, 2013
GSK and the Bill & Melinda Gates Foundation to Accelerate Research into Vaccines
The joint initiative will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration.
Wednesday, October 30, 2013
Malaria Vaccine Could be Available from 2015
GSK candidate reduces disease over 18 Months of follow-up in late-stage study of more than 15,000 infants and young children.
Tuesday, October 08, 2013
GSK and Save the Children Partner to Help Africa
Currently, nearly 7 million children under five die every year from preventable diseases.
Friday, May 10, 2013
Funding boost for GSK’s Open Innovation Research
GSK announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing new treatments for diseases of the developing world.
Wednesday, May 08, 2013
GSK Provides Update on Corporate Responsibility Commitments in 2011 Report
Company publishes its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
Monday, April 16, 2012
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma
GSK intends to commence global regulatory filings in COPD and asthma from mid-2012.
Monday, January 09, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos